HGH Fragment 176-191: preparation and storage
Intended for research use only. Not a medicinal product.
Contents (11 sections)
Native fragment and AOD9604 are distinct
HGH Fragment 176-191 denotes the C-terminal fragment of mature human growth hormone with sequence FLRIVQCRSVEGSCGF. AOD9604 is described as a Tyr-modified 177-191 fragment, YLRIVQCRSVEGSCGF. The first-residue substitution is a chemical difference rather than alternative spelling. Catalogues sometimes conflate these names; a page title cannot determine a vial’s contents. Before preparation, check actual sequence, oxidized or reduced state and expected mass in the certificate. Do not calculate molarity using another fragment’s mass when only a trade name is supplied.
Batch identity and supplied form
Before opening, match the vial name, batch number, certificate of analysis and specification. Establish identity, stated mass, counterion, water, excipients and recommended conditions. “Lyophilized” describes a drying process; it does not establish purity, sterility or exact peptide content. HPLC main-peak area and peptide mass fraction are different measurements: water and salts may contribute little to that chromatogram. If the manufacturer has not established peptide content, label the concentration as calculated from nominal mass.
Mature-hormone and precursor numbering
UniProt P01241 presents human growth hormone as a precursor with a signal peptide. Fragment positions 176-191 refer to mature hormone rather than those same positions in the complete precursor. Establish mature-chain boundaries first. This prevents selection of the wrong segment despite a correct protein accession. Record the fragment sequence, numbering source and cysteine state. Resolve a manufacturer’s alternative numbering before dissolution; similar naming cannot correct an incorrect starting structure.
Two cysteines require a defined state
The fragment contains two cysteine residues, making redox state part of its specification. An intramolecular disulfide and the reduced form have different structures; unwanted intermolecular products can further complicate a sample. DTT, TCEP and arbitrary air oxidation are not neutral ways to “improve a solution.” First establish the form required by the method. Analysis must distinguish the intended form and altered products rather than measure only a general peptide-bond signal. Account for disulfide state when interpreting LC-MS mass.
Mass calculations and working dilutions
An arithmetic example, not a solubility prescription: 2 mg in a final volume of 4 mL gives 0.5 mg/mL, or 500 micrograms/mL. Adding 20 microliters of that stock to 980 microliters of compatible matrix gives 10 micrograms/mL. Then 100 microliters of this solution plus 900 microliters of matrix gives 1 microgram/mL. Use the final volume in the calculation. If the certificate separately establishes peptide mass fraction, apply it according to the labeling convention, without correcting the mass twice. Molarity requires the molecular weight of the confirmed form; do not borrow a value from a related analogue.
Lipid assays have their own confounders
In an adipocyte model, specify glycerol release, free-fatty-acid release or lipid accumulation as the endpoint. These measurements are not direct evidence of GH-receptor binding or full-length growth hormone activity. Fatty-acid-binding albumin, medium composition and cell viability can change the result independently of the peptide. Match those additives in the control matrix. An AOD9604 experiment does not automatically validate a native 176-191 batch; comparisons require separate reagent identification and matched conditions.
Distinguishing sequence from disulfide state
Retention and mass can help distinguish first-residue variants when compared with the appropriate standard. Establish whether sample analysis itself changes redox state. A reducing preparation no longer reports the original disulfide-form fraction; use a parallel nonconverting procedure or another validated approach. Do not automatically dismiss intermolecular disulfide products as insoluble dirt: their formation can explain changed recovery and profile. A correct-mass peak nevertheless does not establish biological action.
Checks after storage
Does a clear solution establish the correct disulfide? Appearance cannot distinguish redox forms. Can a carrier protein be added? Only after checking its effect on analytical and lipid endpoints. Does freezing restore a damaged solution? It cannot reverse an unwanted structural reaction. Compare fresh and stored samples by chemical profile and the chosen functional assay. If they disagree, determine whether peptide, matrix or cell state changed rather than correcting the result using nominal mass.
Stocks for a lipid model
Store the confirmed dry fragment sealed at its specified freezer temperature. For solutions, test whether the required cysteine state survives in the medium throughout the experiment, not only during prior storage. Standardize protein and background fatty acids in adipocyte work. Glycerol measurement needs a matrix control because additives can affect the enzymatic detection reaction. If stored material gives a different result, separate peptide identity, analytical endpoint recovery and cell-state checks. A single general “lipolysis control” cannot answer all three.
End of article
HGH Fragment 176-191
for laboratory research
Packs and current prices on the product page.